Kezar Narrows Loss 37 Percent in Q2

Kezar Life Sciences (NASDAQ:KZR), a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases, released its second quarter 2025 financial results on August 13, 2025. The most important news was a narrower net loss, substantial cost reductions, and the lifting of a partial clinical hold for its lead drug candidate, zetomipzomib, in autoimmune hepatitis. For the quarter, The company reported a GAAP net loss per share of $1.87, an improvement from the $2.96 GAAP loss per share in Q2 2024. No revenue was reported, in line with expectations. The company achieved important regulatory milestones for zetomipzomib while tightening expenses, resulting in a steadier financial base this quarter, yet the path to commercialization remains challenging. Source: Analyst estimates for the quarter provided by FactSet. Kezar Life Sciences is focused on creating therapies for patients with autoimmune diseases—conditions in which the immune system attacks the body’s own healthy tissues. Its main asset is zetomipzomib, a selective immunoproteasome inhibitor. This experimental drug aims to modify the activity of immune cells involved in inflammation while reducing the side effects common with current standard treatments, such as broad immunosuppressive drugs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool